Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the significance of the CheckMate-025 study in renal cell carcinoma (RCC).

The phase III study compared the efficacy of everolimus, the standard of care, versus nivolumab in patients with metastatic RCC who had received at least one VEGF inhibitor. Results showed that there was a significant survival benefit with nivolumab versus everolimus This led to the drug’s FDA approval.

In subgroup analyses of the study, it was concluded that nivolumab demonstrated improved survival over everolimus in all subgroups, including in poor-risk patients.

View more from the 2016 GU Cancer Symposium

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Genitourinary Cancers

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research. 

Immuno-Oncology

Genitourinary Cancers Symposium (ASCO GU)

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the significance of the CheckMate-025 for renal cell carcinoma. 


Dr. Choueiri on Significance of CheckMate-025 Study for RCC